Mazziotta, Francesco
 Distribuzione geografica
Continente #
NA - Nord America 708
EU - Europa 307
AS - Asia 132
AF - Africa 46
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.199
Nazione #
US - Stati Uniti d'America 692
SE - Svezia 131
IT - Italia 84
CN - Cina 75
BG - Bulgaria 37
SG - Singapore 30
CI - Costa d'Avorio 28
FR - Francia 21
NG - Nigeria 17
CA - Canada 16
VN - Vietnam 15
DE - Germania 9
GB - Regno Unito 9
HK - Hong Kong 6
RU - Federazione Russa 6
AU - Australia 5
ES - Italia 2
IN - India 2
JP - Giappone 2
TR - Turchia 2
CZ - Repubblica Ceca 1
ET - Etiopia 1
EU - Europa 1
FI - Finlandia 1
GR - Grecia 1
IE - Irlanda 1
NL - Olanda 1
PL - Polonia 1
RO - Romania 1
UA - Ucraina 1
Totale 1.199
Città #
Chandler 114
Woodbridge 83
Fairfield 76
Ashburn 49
Houston 49
Beijing 40
Seattle 40
Sofia 37
Serra 32
Wilmington 30
Cambridge 29
New York 29
Abidjan 28
Princeton 20
Florence 19
Lagos 17
Lawrence 17
Medford 14
Ottawa 14
Ann Arbor 12
Des Moines 12
Dong Ket 7
Bremen 6
Dearborn 6
Hong Kong 6
Boardman 5
Hebei 5
London 5
San Diego 5
Sydney 5
Boulder 4
Changsha 4
Jiaxing 4
Pisa 4
San Jose 4
Kunming 3
Livorno 3
Nanchang 3
Nanjing 3
Palermo 3
Shenyang 3
Capannori 2
Kilburn 2
Los Angeles 2
Ogden 2
Rome 2
Santa Maria A Monte 2
Singapore 2
Washington 2
Addis Ababa 1
Almere Stad 1
Arezzo 1
Bandra 1
Baotou 1
Brno 1
Carrara 1
Cedar Knolls 1
Chicago 1
Cincinnati 1
Delaware 1
Hefei 1
Helsinki 1
Jinan 1
Jinhua 1
Kocaeli 1
Massa 1
Ningbo 1
North York 1
Palo Alto 1
Paris 1
Phoenix 1
Redwood City 1
San Francisco 1
Tokyo 1
Toronto 1
Tullamore 1
Turin 1
Vinci 1
Wandsworth 1
Warsaw 1
Totale 896
Nome #
Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma 102
The combination of rituximab and bendamustine as first-line treatment is highly effective in the eradicating minimal residual disease in follicular lymphoma: An Italian retrospective study 99
The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia 96
ACUTE T-LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC T-CELL LYMPHOMA. ROLE OF EARLY allo-SCT 93
The onset of monoclonal and oligoclonal gammopathies is a good prognostic factor after allogeneic stem cell transplantation 86
The Onset of Monoclonal and Oligoclonal Gammopathies Is a Good Prognostic Factor after Allogeneic Stem Cell Transplantation 84
Immune Reconstitution after Allogeneic Stem Cell Transplantation: a Pilot Flow-Cytometry Study for T-Cell Sub-Populations 82
Plasma Cell Disorders and Dialysis-Dependent Renal Failure: Safety and Efficacy of Autologous Stem Cell Transplantation 74
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients 72
The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice 67
Safety and Efficacy of Rituximab and Cyclophosphamide in a Case of Resistant Acquired Hemophilia A in Course of Chronic Lymphocytic Leukemia 64
Cytokine Release from Stimulated PBMC after-HSCT: Results of a Post-Transplant Zinc Oral Supplementation Trial (ZENITH). 62
AUTOLOGOUS-STEM CELL TRANSPLANTATION IN DIFFUSE-LARGE B CELL LYMPHOMA: THE TUSCANY EXPERIENCE 61
ACUTE T-LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC T-CELL LYMPHOMA. ROLE OF EARLY allo-SCT 60
AUTOLOGOUS-STEM CELL TRANSPLANTATION IN HODGKIN'S LYMPHOMA: THE TUSCANY EXPERIENCE 55
Activation of the Zinc-sensing receptor GPR39 promotes T cell reconstitution after hematopoietic cell transplant in mice 52
Joint Pain and Arthritis as First Clinical Manifestation of Systemic Amyloidosis and Multiple Myeloma: Case Report and Brief Literature Review 21
Totale 1.230
Categoria #
all - tutte 3.989
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.989


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20198 0 0 0 0 0 0 0 0 0 0 0 8
2019/2020300 28 21 24 12 21 39 48 26 27 21 28 5
2020/2021117 8 6 4 4 8 13 0 4 16 9 21 24
2021/2022184 7 6 2 10 31 23 2 3 12 9 17 62
2022/2023360 47 65 24 31 43 33 5 32 49 3 26 2
2023/2024133 8 12 25 3 13 31 10 5 2 3 8 13
Totale 1.230